Skip to main content
    R

    Rxsight Inc (RXST)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $5.30
    -0.02 (-0.38%)

    Market Cap: $223.06M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rxsight Inc (RXST) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Rxsight reported revenue of $134.48M for the fiscal year ended Dec 31, 2025, down 3.9% from the year before. That year, net income was -$38.94M with a net margin of -29.0%, operating cash flow was -$15.51M and free cash flow was -$19.34M. The quarter ended Sep 30, 2026 had revenue of $24.59M and net income of -$16.22M.

    Revenue and Margins

    The operating margin was -35.8% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from $2.24M, a compound annual rate of 97.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$134.48M-3.9%76.6%-35.8%-29.0%
    Dec 2024$139.93M+57.1%70.7%-26.3%-19.6%
    Dec 2023$89.08M+81.8%60.4%-56.2%-54.6%
    Dec 2022$49.01M+116.9%43.5%-129.2%-136.2%
    Dec 2021$22.59M+53.9%20.0%-233.6%-215.5%
    Dec 2020$14.68M+555.0%11.6%-241.3%187.9%
    Dec 2019$2.24MN/A-81.2%-2055.8%5632.3%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$134.48M$139.93M$89.08M$49.01M$22.59M$14.68M$2.24M
    Cost of revenue$31.47M$40.98M$35.31M$27.68M$18.08M$12.97M$4.06M
    Gross profit$103.01M$98.94M$53.77M$21.33M$4.52M$1.71M-$1.82M
    Research and development$38.55M$34.37M$29.05M$25.98M$24.50M$21.93M$29.57M
    Operating income-$48.19M-$36.86M-$50.09M-$63.32M-$52.79M-$35.41M-$46.07M
    Net income-$38.94M-$27.45M-$48.61M-$66.76M-$48.69M$27.57M$126.22M
    EBITDAN/AN/AN/A-$60.15M-$51.05M$31.25M$130.20M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$24.59M$33.74M$30.89M$32.61M$30.34M$33.64M$37.90M$40.21M$35.31M$34.89M$29.51M$28.58M
    Gross profit$24.59M$33.74M$23.50M$25.26M$30.34M$33.64M$28.33M$28.79M$25.22M$24.25M$20.68M$17.65M
    Operating income-$18.52M-$13.77M-$17.83M-$11.34M-$12.18M-$14.00M-$10.67M-$8.63M-$9.23M-$8.33M-$10.67M-$10.85M
    Net income-$16.22M-$12.10M-$15.88M-$9.15M-$9.82M-$11.79M-$8.19M-$5.94M-$6.34M-$6.08M-$9.10M-$9.18M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $1.16M by $18.79M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$311.81M$318.56M$182.55M$150.16M$192.72M$100.68M$110.43M
    Current assets$287.46M$293.82M$168.41M$134.56M$176.29M$81.50M$90.20M
    Cash and equivalents$19.95M$16.71M$9.69M$11.83M$24.36M$13.99M$7.96M
    Total liabilities$36.13M$37.33M$22.19M$60.26M$54.48M$44.91M$415.04M
    Short-term debt$1.16M$974.00K$1.80M$1.97M$1.53M$1.27M$990.00K
    Long-term debt$0$127.00K$74.00K$40.17M$39.76M$24.40MN/A
    Shareholder equity$275.68M$281.24M$160.36M$89.90M$138.24M-$430.59M-$304.61M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$340.42M$352.70M$303.99M$311.81M$308.53M$309.01M$313.04M$318.56M$310.47M$305.50M$183.16M$182.55M
    Total liabilities$85.51M$89.36M$36.70M$36.13M$32.56M$31.00M$33.73M$37.33M$33.21M$30.29M$19.24M$22.19M
    Cash and equivalents$66.72M$13.35M$17.57M$19.95M$29.63M$40.35M$28.00M$16.71M$16.72M$24.45M$32.65M$9.69M
    Shareholder equity$254.91M$263.34M$267.30M$275.68M$275.97M$278.01M$279.32M$281.24M$277.26M$275.21M$163.93M$160.36M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$15.51M-$16.95M-$41.59M-$58.85M-$44.71M-$35.20M-$40.62M
    Capital expenditures$3.83M$5.44M$4.81M$2.39M$1.94M$2.54M$4.09M
    Free cash flow-$19.34M-$22.39M-$46.41M-$61.24M-$46.65M-$37.74M-$44.70M
    Dividends paidN/AN/AN/A$643.00KN/AN/AN/A
    Share repurchases$0$768.00K$622.00K$587.00K$0$0N/A
    Investing cash flow$16.89M-$99.31M-$22.13M$39.95M-$81.91M$15.59M-$5.87M
    Financing cash flow$1.86M$123.32M$61.52M$6.33M$137.34M$25.24M$1.33M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$45.22M-$9.54M-$10.89M-$1.12M-$1.19M-$4.38M-$8.83M-$4.26M$650.00K-$4.03M-$9.31M-$8.30M
    Capital expenditures$1.17M$1.96M$759.00K$1.14M$581.00K$1.54M$575.00K$847.00K$1.10M$1.52M$1.97M$1.59M
    Free cash flow$44.04M-$11.49M-$11.65M-$2.25M-$1.77M-$5.91M-$9.41M-$5.11M-$453.00K-$5.55M-$11.28M-$9.89M
    Last 12 quarters

    Frequently Asked Questions About RXST

    What is Rxsight's annual revenue?

    Rxsight reported revenue of $134.48M for the fiscal year ended Dec 31, 2025.

    How fast is Rxsight's revenue growing?

    Revenue was down 3.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 40.0%.

    Is Rxsight profitable?

    No. Rxsight reported net income of -$38.94M for the fiscal year ended Dec 31, 2025, with a net margin of -29.0%.

    How much free cash flow does RXST generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$15.51M minus capital expenditures of $3.83M produced free cash flow of -$19.34M.

    How much debt does Rxsight have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $1.16M and cash and equivalents of $19.95M.